PURPOSE: This study was conducted to develop biologically relevant animal models of human lung cancer that are reproducible, inexpensive, and easy to perform. EXPERIMENTAL DESIGN: Human lung adenocarcinoma (PC14PE6), bronchioloalveolar carcinoma (NCI-H358), squamous cell carcinoma (NCI-H226), poorly differentiated non-small cell lung cancer (NCI-H1299 and A549), or small cell lung cancer (NCI-H69) cells in Matrigel were injected percutaneously into the left lungs of nude mice. The growth pattern of the different lung cancer tumors was studied. For PC14PE6 and NCI-H358, the growth pattern in the subcutis and the response to paclitaxel were also studied. RESULTS: As is observed for human primary lung cancer, tumors formed from a single focus of disease and progressed to a widespread and fatal thoracic process characterized by diffuse dissemination of lung cancer in both lungs and metastasis to intra- and extrathoracic lymph nodes. When the lung cancer cell lines were implanted s.c., systemic therapy with paclitaxel induced tumor regression. However, only a limited therapeutic response to paclitaxel was observed when the same cells were implanted orthotopically into the lung. Immunohistochemical analysis of tumor tissue revealed increased expression of the proangiogenic factors interleukin 8, basic fibroblast growth factor, and vascular endothelial growth factor/vascular permeability factor. CONCLUSIONS: Our orthotopic models of human lung cancer confirm the "seed and soil" concept and likely provide more clinically relevant systems for the study of both non-small cell lung cancer and small cell lung cancer biology, and for characterizing novel therapeutic strategies.
PURPOSE: This study was conducted to develop biologically relevant animal models of humanlung cancer that are reproducible, inexpensive, and easy to perform. EXPERIMENTAL DESIGN:Humanlung adenocarcinoma (PC14PE6), bronchioloalveolar carcinoma (NCI-H358), squamous cell carcinoma (NCI-H226), poorly differentiated non-small cell lung cancer (NCI-H1299 and A549), or small cell lung cancer (NCI-H69) cells in Matrigel were injected percutaneously into the left lungs of nude mice. The growth pattern of the different lung cancer tumors was studied. For PC14PE6 and NCI-H358, the growth pattern in the subcutis and the response to paclitaxel were also studied. RESULTS: As is observed for humanprimary lung cancer, tumors formed from a single focus of disease and progressed to a widespread and fatal thoracic process characterized by diffuse dissemination of lung cancer in both lungs and metastasis to intra- and extrathoracic lymph nodes. When the lung cancer cell lines were implanted s.c., systemic therapy with paclitaxel induced tumor regression. However, only a limited therapeutic response to paclitaxel was observed when the same cells were implanted orthotopically into the lung. Immunohistochemical analysis of tumor tissue revealed increased expression of the proangiogenic factors interleukin 8, basic fibroblast growth factor, and vascular endothelial growth factor/vascular permeability factor. CONCLUSIONS: Our orthotopic models of humanlung cancer confirm the "seed and soil" concept and likely provide more clinically relevant systems for the study of both non-small cell lung cancer and small cell lung cancer biology, and for characterizing novel therapeutic strategies.
Authors: Osamu Takahashi; Ritsuko Komaki; Paul D Smith; Juliane M Jürgensmeier; Anderson Ryan; B Nebiyou Bekele; Ignacio I Wistuba; Jörg J Jacoby; Maria V Korshunova; Anna Biernacka; Baruch Erez; Keiko Hosho; Roy S Herbst; Michael S O'Reilly Journal: Clin Cancer Res Date: 2012-01-24 Impact factor: 12.531
Authors: Rajesha Rupaimoole; Da Yang; Rehan Akbani; Chad V Pecot; Cristina Ivan; Chunhua Lu; Sherry Wu; Hee-Dong Han; Maitri Y Shah; Cristian Rodriguez-Aguayo; Justin Bottsford-Miller; Yuexin Liu; Sang Bae Kim; Anna Unruh; Vianey Gonzalez-Villasana; Li Huang; Behrouz Zand; Myrthala Moreno-Smith; Lingegowda S Mangala; Morgan Taylor; Heather J Dalton; Vasudha Sehgal; Yunfei Wen; Yu Kang; Keith A Baggerly; Ju-Seog Lee; Prahlad T Ram; Murali K Ravoori; Vikas Kundra; Xinna Zhang; Rouba Ali-Fehmi; Ana-Maria Gonzalez-Angulo; Pierre P Massion; George A Calin; Gabriel Lopez-Berestein; Wei Zhang; Anil K Sood Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Zheng Yun Cui; Jin Seok Ahn; Jee Yun Lee; Won Seog Kim; Ho Yeong Lim; Hyun Jung Jeon; Soo Won Suh; Jin Hoon Kim; Won Ho Kong; Ji Min Kang; Do Hyun Nam; Keunchil Park Journal: Cancer Res Treat Date: 2006-12-31 Impact factor: 4.679
Authors: Mary C M Weiser-Evans; Xue-Qing Wang; Jay Amin; Vicki Van Putten; Rashmi Choudhary; Robert A Winn; Robert Scheinman; Peter Simpson; Mark W Geraci; Raphael A Nemenoff Journal: Cancer Res Date: 2009-02-10 Impact factor: 12.701